Annexon, Inc. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Annexon Inc. entered into a loan and security agreement with Oxford Finance LLC dated July 30, 2026, for up to $200 million in term loans. The company drew $50 million (Term A Loan) at closing. An additional $100 million becomes available upon achievement of FDA approval milestones for vonaprument (Geographic Atrophy) and tanruprubart (Guillain-Barré Syndrome), with the remaining $50 million (Term E Loan) subject to lender discretion. Interest accrues at 1-Month CME Term SOFR plus 4.60% (floor 7.60%); loans mature July 1, 2031 (or 2032 if extended), with a 1.00% facility fee, prepayment fees of 1–2%, and a final payment tied to loan amount.
Why this rating
Non-dilutive capital of ~$50M drawn (20% of ~$244M market cap) eases near-term cash needs; milestone-based tranches reduce immediate dilution but introduce execution risk tied to FDA approvals. Material for a clinical-stage biotech.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.